Claims
- 1. A pharmaceutical dry-coated tablet for oral use, which comprises:a. a core containing an active principle which may cause lesions to the gastric mucosa as a side effect; and b. a coating of said core which contains as the main component dry sucralfate gel in granular and porous solid form in which the granules present a particle size distribution of between 100 and 1000 μm, an apparent density of the powder of between 0.7 and 0.9 g/ml, and a settling index of between 5 and 15%.
- 2. The pharmaceutical dry-coated tablet according to claim 1, wherein the active principle that may cause lesions to the gastric mucosa is selected from the group consisting of acetylsalicyclic acid, ibuprofen, ketoprofen, diclofenac, piroxicam and nimesulide.
- 3. The pharmaceutical dry-coated tablet according to claim 1, wherein dry sucralfate gel in granular and porous solid form contains a gel-protective agent, in quantities expressed as weight of sucralfate contained in sucralfate gel with respect to weight of gel-protective agent, of between 0.5:1 and 1.5:1.
- 4. The pharmaceutical dry-coated tablet in granular and porous solid form according to claim 2, wherein said gel-protective agent is selected from the group consisting of mannitol, sorbitol, glucose, sucrose, lactose, xylitol and polyalcohols.
Priority Claims (1)
Number |
Date |
Country |
Kind |
MI98A1785 |
Jul 1998 |
IT |
|
Parent Case Info
This application is a division of Ser. No. 09/744,869 filed Jan. 29, 2001, which is a 371 of PCT/EP99/03879 filed Jun. 4, 1999.
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9605843 |
Feb 1996 |
WO |